Hundreds of kindergarten pupils are poisoned after cooks use PAINT to decorate meals
More than 200 children in northwestern China fell ill with potential lead poisoning from date cakes and corn rolls, state media said on Tuesday.
Investigators found 'abnormal' levels of lead in the blood of 233 children at Peixin Kindergarten in Tianshui city, according to state broadcaster CCTV.
Of those, 201 of the children are being treated in hospital.
Food safety scandals were once common in China, where tainted milk formula made hundreds of thousands of babies ill in 2008 and was linked to six deaths.
City authorities investigated the head of the kindergarten last week after receiving reports that children were falling ill.
A parent told state-run Jimu News tabloid last week that children had been experiencing stomach pain and nausea, and that some of their teeth turned black.
Testing revealed that samples of three-colour steamed date cakes and corn rolls contained more than 2,000 times the national safety standard for food contaminants.
The cake, served at breakfast, returned a reading of 1,052 milligrams per kilogram and the roll, served at another meal, was found with 1,340 milligrams per kilogram.
The nationwide limit for lead in wheat and starch is 0.5 milligrams per kilogram, according to Chinese government records.
CCTV said security footage shows kitchen staff adding packaged yellow colouring to a flour mix used in both contaminated dishes.
The kindergarten's principal, surnamed Zhu, and an investor surnamed Li have been detained along with six other people, CCTV said. Two others are on 'bail pending trial'.
Investigators found that Zhu and Li allowed kitchen staff to produce food using paint pigments purchased online that were later found to contain lead and were marked inedible.
Testing among children attending other kindergartens linked with Peixin returned normal results.
Food safety standards have generally improved across China but revelations last year that cooking oil had been transported in containers also used to carry fuel sparked outrage across Chinese social media.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
3 hours ago
- Daily Mail
Pill that costs just pennies a day linked to decreased risk of dementia, study suggests
Doctors are zeroing in on ways to prevent dementia, and the secret weapon could be an inexpensive drug that has served as the backbone for diabetes treatment for decades. Long before Ozempic splashed onto the scene, transforming type 2 diabetes treatment, there was metformin. Used for about 100 years, metformin lowers the amount of sugar the liver pumps out and helps the body respond to insulin better. It has been the first-line treatment for more than 70 percent of people newly diagnosed with type 2 diabetes. Doctors have suggested through observational studies for several years that the mainstay of diabetes, which roughly 19 million people take for $2 to $20 per month, could have preventive power. Still, evidence has been mixed, with some studies suggesting the drug exacerbates the development of Alzheimer's disease, just one type of dementia, and several others saying it has a protective effect on the brain. Now, doctors from Taipei Medical University in Taiwan are the latest to make the case for the latter. They found that, in half a million overweight and obese people without diabetes, those who took metformin had a lower risk of developing dementia or dying from any cause, regardless of their BMI. Similar to type 2 diabetes, obesity is a risk factor for dementia. Being severely overweight lowers the body's defenses against the damage dementia inflicts on the brain and causes chronic inflammation, potentially damaging nerve cells. Until now, research into metformin as a dementia preventative has primarily focused on people with diabetes. The latest report from Taiwanese researchers is the first to use real-world data to investigate the possibility in people with obesity. The scientists noted the real-world data reflects a diverse population, making the study's findings widely applicable. They used an electronic health records database covering millions of patients from 66 US healthcare systems, including hospitals, specialty centers, and clinics. The researchers said: 'Since central nervous system inflammation and neuroinflammation are crucial factors in the development and progression of neurodegenerative diseases, the anti-inflammatory and antioxidative effects of metformin are especially beneficial in patients with obesity. 'Regular, long-term use of metformin may be an efficient way to prevent dementia.' The study included about 905,000 people in total, split evenly into two groups: those on and those not on metformin. They were matched to be similar in age, health, and other factors for a fair comparison. The metformin group had been prescribed the drug at least twice in their lives for at least six months. The study did not explicitly state why people had been prescribed the drug, but it can be used to treat more than just diabetes, such as prediabetes, those with a metabolic disorder that contributes to obesity, and for polycystic ovary syndrome. Researchers categorized their study subjects, all adults over 18, into four groups: overweight (BMI 25–29.9), Obese class I (BMI 30–34.9), Obese class II (BMI 35–39.9) and morbidly obese (BMI over 40). After following patients for 10 years, those who took metformin had a lower risk of developing dementia across all BMI groups. The amount of risk reduction varied slightly depending on weight, but two of the groups saw significant results. People with a BMI of 30 to 34.9 had a dementia risk about eight percent lower than non-users, while those with a BMI between 25 and 29.9 had a risk about 12.5 percent lower. People with a BMI of 35 to 39.9 had a four percent lower risk, which researchers deemed statistically insignificant, potentially due to a smaller sample size. There was no significant difference in people with a BMI over 40. When looking at death from any cause, metformin users also had a significantly lower risk across all BMI categories. Metformin's effect on death risk was stronger than its effect on dementia risk. Those with a BMI between 25 and 29.9 had a 28 percent lower risk of death, while those with a BMI of 30 to 34.9 had a 27 percent lower risk. People with a BMI of 35 to 39.9 had a 28 percent lower risk of death, and people with a BMI of 40 or above saw a 26 percent lower risk. The Taipei team's findings were published in the journal Diabetes, Obesity and Metabolism. Scientists attribute metformin's recently explored impact on cognitive health and dementia to factors unique to the drug and the condition it treats. A type 2 diabetes diagnosis is a leading risk factor for dementia, with one sweeping review in 2013 finding that diabetes patients have a 73 percent higher likelihood of developing dementia and a 56 percent higher likelihood of developing Alzheimer's. Both conditions affect millions in the US. Around 35 million Americans have type 2 diabetes, while an estimated 7million have dementia, including roughly four to 6 million with Alzheimer's disease. Several studies have resulted in compelling evidence that supports metformin's anti-dementia abilities. In 2020, Australian researchers followed over 1,000 dementia-free seniors aged 70 to 90 from Sydney for up to six years, testing their memory and thinking skills at two and six years. The study looked at three main groups: people with type 2 diabetes who were taking metformin, those with diabetes who were not, and people without diabetes. The participants in the study, who did not have dementia at the start, were tested at two years and again at six years for their in-depth memory and executive functioning. After accounting for other health factors, researchers found that the metformin group had an 81 percent lower risk of dementia compared to those with diabetes who weren't on metformin. People with diabetes who didn't take metformin were nearly three times more likely to develop dementia than people without diabetes. Brain scans and thinking tests also suggested that metformin users experienced a slower decline in cognitive abilities, particularly in decision-making and overall brain function.
The Independent
5 hours ago
- The Independent
What is the ‘herb of grace' and how does it benefit your health?
Bacopa Monnieri, also known as brahmi or the 'herb of grace,' has been utilized for centuries in Indian Ayurveda traditional medicine. It is believed to offer brain -boosting benefits, primarily through its antioxidant properties that help protect the brain by stimulating the body's natural defense system. The herb functions as an adaptogen, potentially reducing stress by interacting with the hypothalamic-pituitary-adrenal axis, which regulates the body's stress response. Studies indicate that Bacopa Monnieri can reduce inflammation in the central nervous system and alleviate related pain, with chronic inflammation being linked to various health issues. While generally considered safe, not all risks have been thoroughly studied; it is advisable to consult a doctor and opt for supplements verified by a third party.
Daily Mail
10 hours ago
- Daily Mail
Terrifying warning that deadly new China virus is already HERE... as experts warn what to watch out for: 'Very worrying'
A mosquito-borne virus that leaves victims in crippling pain and has triggered Covid-era restrictions in China is already in the US, experts say. Chikungunya virus can cause sudden, agonizing joint pain in the hands and feet, sometimes so severe that it leaves sufferers unable to move normally for months. Your browser does not support iframes.
